Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Other Non-Current Assets (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Other Non-Current Assets for 14 consecutive years, with $7688.0 as the latest value for Q1 2026.

  • Quarterly Other Non-Current Assets changed 0.0% to $7688.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7688.0 through Jan 2026, changed 0.0% year-over-year, with the annual reading at $7688.0 for FY2025, 0.0% changed from the prior year.
  • Other Non-Current Assets for Q1 2026 was $7688.0 at PharmaCyte Biotech, roughly flat from $7688.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $2.0 million in Q1 2024, with the low at $7688.0 in Q1 2022.
  • Average Other Non-Current Assets over 5 years is $132957.5, with a median of $7688.0 recorded in 2022.
  • The sharpest move saw Other Non-Current Assets skyrocketed 26070.66% in 2024, then crashed 99.62% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $7688.0 in 2022, then changed by 0.0% to $7688.0 in 2023, then changed by 0.0% to $7688.0 in 2024, then changed by 0.0% to $7688.0 in 2025, then changed by 0.0% to $7688.0 in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $7688.0, $7688.0, and $7688.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.